| Protocol ID | NCT02449278 |
| Registration Date | 2015-05-20 |
| Status | Unknown Status |
| Sponsor | Wuhan University |
| Country | China |
| Industry | not industry |
| Blinding | unblinded |
| Center Type | singel-center RCT |
| Scope | national RCT |
| First Patient In | 2015-10-01 |
| Last Patient Out | 2025-10-01 |
| Publication | n |
| Gender % | ALL |
| Mean Age | 18 Years - 65 Years |
NCT02449278
The Palliative Benefit of Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center - NHL04 Trial
| Field |
CLAUDE
claude-sonnet-4-20250514 Thinking: claude-opus-4-20250514 5671ms / 11536 tok |
GLM
glm-5.1 7257ms / 10070 tok |
OPENAI
gpt-4o Thinking: o3 3239ms / 9890 tok |
Review |
|---|---|---|---|---|
| rct_type | parallel RCT | parallel RCT | parallel RCT | OK |
| cancer_status | Cancer | Cancer | Cancer | OK |
| non_cancer_spec | N/A | N/A | N/A | OK |
| setting_patient | outpatient | outpatient | outpatient | OK |
| setting_place |
hospital
other → hospital
shaky reasoning✓ Unanimous
Initial: other
Requery: hospital — This is a radiation therapy trial requiring specialized equipment and facilities for delivering precise radiotherapy treatments (ISRT and IFRT), which are typically only available in hospital-based cancer centers.
|
hospital
hospital → hospital
shaky reasoning✓ Unanimous
Initial: hospital
Requery: hospital — The intervention requires 21-day inpatient cycles of chemotherapy followed by consolidation radiotherapy, both of which are typically administered in a hospital cancer center.
|
hospital
hospital → hospital
shaky reasoning✓ Unanimous
Initial: hospital
Requery: hospital — The intervention involves radiotherapy, which is typically delivered in a hospital setting, and patients likely need to be physically present for the treatment.
|
OK |
| feasibility | fully powered RCT | fully powered RCT | fully powered RCT | OK |
| intervention_pharmacologic | yes | yes | yes | OK |
| intervention_chemo_immuno_radio | yes | yes | yes | OK |
| intervention_complementary | no | no | no | OK |
| intervention_device | no | no | no | OK |
| intervention_psychological | no | no | no | OK |
| intervention_complex |
yes
yes → yes → no
shaky reasoning✗ No consensus
Initial: yes
Requery: yes — The intervention combines chemotherapy (pharmacologic) with consolidation radiotherapy (physical/radiation therapy), representing two distinct treatment modalities working together in sequence for advanced-stage DLBCL.
Thinking: no — Standard oncology combined modality therapy (chemotherapy followed by consolidation radiation) comparing radiation field sizes, not a complex multicomponent intervention.
|
no
no → no
shaky reasoning✗ No consensus
Initial: no
Requery: no — The intervention consists of standard combination chemotherapy (a single pharmacologic modality) followed sequentially by a single radiation modality to compare field sizes, which represents co-administered treatments rather than interacting, multi-component complex intervention.
|
no
no → no → yes
shaky reasoning✗ No consensus
Initial: no
Requery: no — The intervention consists of a standard chemotherapy regimen followed by radiotherapy, which is a common sequential treatment approach in oncology and does not combine multiple distinct types of interventions.
Thinking: yes — Patients receive both systemic chemotherapy (drugs) and subsequent consolidation radiotherapy, integrating two distinct treatment categories into one regimen.
|
|
| intervention_acp | no | no | no | OK |
| intervention_music | no | no | no | OK |
| intervention_screening | no | no | no | OK |
| intervention_palliative | no | no | no | OK |
| intervention_education | no | no | no | OK |
| intervention_digital | no | no | no | OK |
| intervention_other | no | no | no | OK |
| outcome_symptom |
no
no → no
shaky reasoning✓ Unanimous
Initial: no
Requery: no — Primary outcomes focus on progression-free survival and adverse events, while secondary outcomes measure overall survival and disease progression rates, with no validated symptom assessment instruments mentioned.
|
no
yes
shaky reasoning✓ Unanimous
Initial: yes
|
no
no → no
shaky reasoning✓ Unanimous
Initial: no
Requery: no — The trial's primary and secondary outcomes focus on progression-free survival, overall survival, and adverse events, none of which are direct symptom measures using validated symptom instruments.
|
OK |
| outcome_qol | no | no | no | OK |
| outcome_dignity | no | no | no | OK |
| outcome_cost | no | no | no | OK |
| outcome_other | yes | yes | yes | OK |
| pharmacologic_sub | chemotherapy | chemotherapy | chemotherapy | OK |